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ABSTRACT
INTRODUCTION: Nowadays Gla-rich protein (GRP) is recognized as a novel biomarker playing a pivotal 
role in the crosstalk between chronic inflammation and vascular calcification.
AIM: The aim of this article is to study the link between circulating GRP, cardiovascular pathology, and 
the degree of arterial calcification evaluated by the coronary arterial calcium score (CACS) in a Bulgarian 
population sample.
MATERIALS AND METHODS: Adult participants (n=81) of both genders were divided into: controls 
(n=41)—subjects with estimated moderate-to-high risk without known cardiovascular diseases (CVDs) and 
a combined CVD group (n=40)—patients with paroxysmal or persistent atrial fibrillation in sinus rhythm, 
and heart failure subjects with preserved ejection fraction. A structured interview was carried out for 
evaluation of the classical CVD risk factors. CACS was determined by multislice computed tomography. 
Routine laboratory parameters were extracted from medical records. Serum levels of total GRP, matrix Gla 
protein, and osteocalcin were estimated by commercial ELISA kits. Standard statistical methods (descriptive 
statistics, Student’s t-test and Spearman’s correlation) were applied. Statistical significance was considered 
at p<0.05.
RESULTS: Significantly lower GRP levels were established in patients with coronary calcium compared to 
those without calcium deposits. Clear tendency for decreased levels of GRP was observed in the combined 
CVD group vs controls. Circulating GRP significantly correlates with uncarboxylated matrix Gla protein. 
An association between serum GRP, CRP, and low-density lipoproteins (LDLs) was demonstrated.
CONCLUSION: This study adds new information regarding the role of circulating GRP as a new player in 
calcification inhibition. Our findings illuminate the link between total circulating GRP, CVD pathology, 
and the degree of coronary calcification.
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of articular and immune cells (6,8). GRP calcium-
binding properties and its association to calcifica-
tion processes indicate that its function might be as-
sociated with prevention of calcium-induced signal-
ing pathways and direct mineral binding leading to 
blockage of crystal formation and maturation. High 
levels of GRP are found in sites of pathological cal-
cification possibly due to its capability to bind cal-
cium phosphate crystals directly (11). An impaired 
γ-carboxylation status of GRP is considered to be 
associated with pathological calcification, includ-
ing vascular calcification, osteoarthritis, and cer-
tain cancers (11,12). It is considered that circulating 
GRP is a systemic inhibitor of ectopic calcification 
through its involvement in the inhibition of Ca/P 
mineral crystal formation and maturation, with pro-
found consequences on vascular calcification (7).
The studies examining the role of circulating 
GRP as a novel marker of vascular calcification and 
inhibitor of inflammation are extremely scarce. To 
our knowledge, circulating GRP levels and their link 
to CVD have not examined in Bulgarian population.
AIM
The aim of our pilot study was to examine the 
link between circulating GRP, CVD pathology and 
the degree of arterial calcification evaluated by the 
CAC score in Bulgarian population sample. 
MATERIALS AND METHODS
Patients and Methods 
The current study included 81 Bulgarian pa-
tients who were admitted to St. Marina University 
Hospital Varna between October 2018 and January 
2020. In the control group were included 41 subjects 
who were estimated to be with moderate-to-high 
risk for CVD but without known CVD. The other 40 
subjects formed the combined CVD group—23 pa-
tients with paroxysmal and persistent atrial fibril-
lation (AF) and 17 patients with heart failure (HF) 
with preserved ejection fraction (ejection fraction 
>40%, HFpEF) in sinus rhythm at the time of hos-
pitalization. Information about age and history of 
CVD, smoking status, presence and treatment of ar-
terial hypertension, hyperlipidemia, type 2 diabe-
tes mellitus, and current use of anticoagulant med-
ication were collected through a structured inter-
view. Hypertension was defined as blood pressure 
INTRODUCTION
As cardiovascular diseases (CVDs) are one of 
the major causes of death worldwide, a significant 
part of scientific research is focused on elucidating 
the molecular mechanisms underlying their devel-
opment and progression. Vascular calcification (VC) 
is a process of calcium phosphate deposition in the 
vessel wall due to impaired balance between the reg-
ulatory mechanisms that contribute to the mineral-
ization of the vessel wall and those that inhibit it (1). 
VC is a multifactorial process, but the loss of calci-
fication inhibitors is a major mechanism for its en-
hancement (2,3).
Gla-rich protein (GRP) is a circulating vitamin 
K-dependent protein, also known as an upper zone of 
growth plate and cartilage matrix associated protein 
(UCMA) (4). A decade earlier GRP has been suggest-
ed to act as a negative regulator of osteogenic differ-
entiation, a novel secretory cartilage-specific protein 
with implications in osteogenesis, a modulator of cal-
cium availability in the extracellular matrix (ECM), 
and as a potential inhibitor of soft tissue calcifica-
tion (4,5). In addition, it plays а role as an inhibitor of 
pathological VC and as an anti-inflammatory agent 
in the cardiovascular system (6,7). Nowadays GRP is 
recognized as a novel biomarker, which plays a piv-
otal role in the crosstalk between chronic inflamma-
tion and calcification in the articular, renal and car-
diovascular systems (8).
Similarly to matrix Gla protein (MGP), another 
vitamin K-dependent protein, acting as local inhib-
itor of soft tissue calcification and vascular miner-
alization (9,10), GRP γ-carboxylation is essential for 
its calcification inhibitory function (8). In the study 
of Viegas et al. (6) it was demonstrated that GRP ex-
pression and accumulation are upregulated by a cal-
cification process and possibly GRP is a component 
of the fetuin-A-MGP calcification inhibitory system. 
Moreover, it was demonstrated that GRP is included 
in the fetuin-A-MGP complex at the sites of valvular 
calcification. Also, only the γ-carboxylated GRP in-
hibits effectively calcification and osteochondrogen-
ic differentiation through α-smooth muscle actin up-
regulation and osteopontin downregulation. In the 
same in vitro study it was demonstrated that addi-
tion of carboxylated GRP is able to reduce both vas-
cular calcification and proinflammatory responses 
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(BP) >140/90 mmHg at the time of examination or 
with a history of elevated BP and on antihyperten-
sive medication. According to the cutoff values of 
ESC Guidelines, hyperlipidemia was defined as ele-
vated total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C) or triglycerides (TG) or by the 
use of lipid-lowering medications (13). All patients 
were physically examined for heart rate, blood pres-
sure, weight, height, and waist circumference (WC). 
Body mass index (BMI) was calculated according to 
the standard formula. Patients with proven ischemic 
heart disease or stroke, cardiomyopathy, type 1 dia-
betes, chronic renal disease stage IV or more, known 
thyroid gland disease, and active cancer were exclud-
ed from the study.
The study was approved by the local Ethical 
Committee at the Medical University of Varna (Pro-
tocol No 75/ 07.06.2018). Written informed consent 
was obtained from all participants in the study.
Coronary Artery Calcification Measurement
All participants were examined on a multi-slice 
computed tomography in order to assess the pres-
ence of coronary artery calcification. CAC scans 
were performed on a Siemens Somatom Definition 
(Dual Source 2×64) CT scanner (Erlangen, Germa-
ny) using standardized imaging protocols and were 
interpreted by a single trained physician  blinded to 
the clinical characteristics of the patients. Coronary 
artery calcification was defined as a lesion above 130 
Hounsfield units, with an area equal to three pix-
els. CAC score (CACS) was calculated using the Ag-
atston criteria (14). The presence of CAC was defined 
as an Agatston score >0 Agatston units (AU). Ac-
cording to the CACS results, the patients were clas-
sified into one of the following categories: CACS=0 
AU (no coronary calcium), CACS>0 AU (presence of 
coronary calcium).
Biochemical Measures 
Data for routine biochemical parameters, lipid 
profile parameters (TG, TC, HDL cholesterol, LDL 
cholesterol) and C-reactive protein (CRP) were ex-
tracted from the medical documentation. Fasting 
venous blood was drawn at admittance in the clin-
ic. Blood samples were centrifuged at 1600xg for 15 
min, and blood plasma and serum were separated 
and stored at -80oC until analysis of specific labora-
tory parameters. A commercial ELISA kits based on 
specific competitive mono-antibodies were used for 
measuring the plasma levels of total GRP (Develop, 
China), circulating ucMGP (Cusabio, Wuhan, Chi-
na), uncarboxylated (ucOC), and carboxylated osteo-
calcin (cOC) (BlueGene Biotech, Shanghai, China). 
The ratio between the concentrations of circulating 
ucOC and cOC (UCR) was calculated and used as an 
inverse indicator of vitamin K status. A lower OCR 
reflects good vitamin K status (15). 
Statistical Analysis 
Data are presented as mean±standard devia-
tion, or number (n) and percentage. Statistical anal-
ysis was performed by GraphPad software version 
7 (GraphPad Software, San Diego, CA USA) and 
SPSS v.23 (SPSS Inc., Chicago, IL, USA). Student’s t-
test was used to compare the means of two groups. 
Spearman correlation analysis was used for evalua-
tion of the associations between the tested variables. 
Statistical significance was considered at p<0.05. 
RESULTS 
Table 1 represents the baseline patients’ charac-
teristics. Significant differences between CVD and 
non-CVD patients were indicated for age, anthro-
pometric measurements, AH duration, and smoking 
status. CACS for CVD group was three times high-
er compared to the non-CVD controls. Significant-
ly higher values were indicated for serum glucose, 
creatinine, urea, and uric acid. More pronounced 
changes of the tested lipid parameters were found for 
LDL cholesterol.
We indicated a clear tendency for a decrease 
in circulating GRP levels for CVD patients vs. non-
CVD controls (Fig. 1). Although non-significant, the 
same trend was preserved when the CVD partici-
pants were divided according to CVD pathology—
lower GRP values were found for the HF group than 
those for AF patients (1.06±0.8 vs. 1.29±1.02 ng/mL).
For assessing the changes in circulating GRP to 
the presence or absence of arterial calcium deposits, 
we stratified the patients according to their CACS. 
The data reveal a significantly lower circulating GRP 
(with 23.4%) in the group with coronary calcium 
(CACS>0) vs. patients without CAC (CACS=0) (Fig. 
2). 
To assess the link between circulating GRP 
and the tested risk factors for atherosclerosis we per-
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Parameter ControlMean ± SD (n = 41)
CVD Patients
Mean ± SD (n = 40) p
Age (years) 53.39 ± 9.81 68.88 ± 7.03 0.001
Male gender (%) 39.0 32.5 0.352
BMI (kg/m2) 27.65 ± 5.66 30.36 ± 5.61 0.039
WC (cm) 92.00 ± 16.02 104.89 ± 12.91 0.001
AH duration (years) 6.11 ± 5.21 12.05 ± 8.02 0.001
Smoking duration (years) 17.92 ± 8.69 28.69 ± 12.66 0.013
Diabetes duration (years) 5.50 ± 3.54 12.93 ± 12.5 0.209
CACS (AU) 80.84 ± 285.45 353.17 ± 560.66 0.007
Glucose (mmol/L) 5.81 ± 0.82 7.44 ± 3.34 0.004
Urea (mmol/L) 5.83 ± 0.87 8.37 ± 4.99 0.050
Creatinine (mmol/L) 68.05 ± 13.50 83.24 ± 23.76 0.001
Uric acid (mmol/L) 318.28 ± 111.36 388.96 ± 99.51 0.009
Total cholesterol (mmol/L) 5.25 ± 1.01 4.86 ± 1.19 0.126
Triglycerides (mmol/L) 1.41 ± 1.04 1.47 ± 0.87 0.765
HDL cholesterol (mmol/L) 1.39 ± 0.41 1.44 ± 0.45 0.575
LDL cholesterol (mmol/L) 3.26 ± 0.76 2.79 ± 0.92 0.016
CRP (mg/L) 0.61 ± 0.45 9 5.54 ± 6.19 0.282
GRP (ng/mL) 1.11 ± 0.78 0.91 ± 0.77 0.080
ucMGP (µg/mL) 4.42 ± 3.37 5.69 ± 4.94 0.057
Abbreviations: BMI—body mass index; AH—arterial hypertension; CACS—coronary arterial calcium score; HDL—high-density 
lipoprotein; LDL—low-density lipoprotein; CRP—C-reactive protein; GRP—Gla-rich protein; ucMGP—uncarboxylated matrix Gla 
protein.
Table 1. Patients’ baseline characteristics
Fig. 1. Circulating serum GRP levels in controls  
(non-CVD patients) and in the combined CVD group  
(AF and HF patients). 
Data are given as mean ±SD; statistical significance was con-
sidered at p<0.05; GRP—Gla-rich protein; CVD—cardiovascu-
lar disease; AF—atrial fibrillation; HF—heart failure with pre-
served ejection fraction.
Fig. 2. Circulating serum GRP levels in patients without 
coronary calcium (CACS=0) and in participants with ar-
terial calcium deposits (CACS>0). 
Data are given as mean ±SD; statistical significance was con-
sidered at p<0.05; GRP—Gla-rich protein; CACS—coronary ar-
terial calcium score.
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formed Spearman correlation analysis for controls 
and CVD patients. Of the tested lipid parameters 
negative correlation with borderline significance was 
found for total cholesterol (r=–0.287; p=0.056) and 
triglyceride levels (r=–0.293; p=0.051) for the com-
bined CVD group. For the same group a negative 
trend for a decrease in circulating GRP with CRP as 
a marker of inflammation (r=–0.187; p=0.416) was 
indicated. In the control non-CVD group we found 
significant negative associations only with smoking 
duration (r=–0.417; p=0.0197). Serum GRP tend-
ed to decrease with CACS for CVD and non-CVD 
patients. Circulating GRP correlated positively with 
circulating ucMGP for the control subjects (r=0.288; 
p=0.05) and for the combined CVD group (r=0.561; 
p<0.0001). 
When the patients were divided according to 
their CACS, significant moderate association was 
found between circulating GRP and ucMGP and 
negative correlation with smoking status for both 
groups with or without coronary calcium. CRP, TC, 
TG and LDL-C tended to increase with the decrease 
of serum GRP (Table 2).
We did not found interrelations between circu-
lating GRP, anthropometric parameters, duration of 
arterial hypertension, diabetes, both cOC and ucOC 
or OCR levels.
DISCUSSION
Our study aimed to estimate the relationship 
between circulating total GRP with CVD patholo-
gy and vascular calcification. In CVD patients (com-
bined AF + HF group), we have also examined the in-
teraction between GRP, certain risk factors for CVD 
and with the circulating levels of ucMGP as proven 
VC inhibitor. 
We observed a tendency, although not signifi-
cant, for a decrease in circulating levels of total GRP 
in the CVD patients, which is consistent with other 
studies (6,16,17). In the study of Viegas et al. (7), the 
levels of serum GRP sharply decrease in chronic kid-
ney disease (CKD) patients with the severity of CKD 
pathology, e.g. from stage 2 CKD to stage 4 CKD. 
Our data also revealed lower serum GRP not only for 
the combined CVD group, but also for patients with 
more severe CVD pathology, such as heart failure.
Vascular calcification is a process under strict 
regulation of calcium and phosphate deposition in 
the intima and media layers of the vessel wall and in 
cardiac valves. The inhibition of mineral crystal for-
mation is critical for prevention the destructive ef-
fects of calcium deposits and ectopic calcification. 
This process is actively inhibited by the functional 
calcification inhibitors, including MGP and fetuin-
A (18). GRP is another constitutive component of 
the inhibitory system composed of MGP and fetuin-
A preventing crystal formation and maturation (7). 
It is assumed that deficiency in GRP may result in 
increased mineral maturation promoting VC (7). In 
agreement with these data our study revealed signifi-
cantly lower GRP levels in patients with coronary ar-
tery calcium (CACS>0) compared to those without 
coronary calcium (CACS=0).
In the present study, we found a positive associ-
ation between circulating GRP and ucMGP in both 
CVD patients and in those with coronary calcium. 
To our knowledge, this is the first study examining 
the relation between these two inhibitory proteins of 
Tested Parameter CACS > 0 CACS = 0Spearman r; p Spearman r; p
Smoking duration (years) –0.389; p = 0.045 –0.386; p = 0.084
TC (mmol/L) –0.189; p = 0.193 –0.048; p = 0.764
TG (mmol/L) –0.148; p = 0.309 –0.108; p = 0.496
LDL-C (mmol/L) –0.155; p = 0.293 –0.054; p = 0.733
CRP (mg/L) –0.044; p = 0.871 –0.500; p = 0.267
ucMGP (μg/mL) r = 0.563; p ≤ 0.0001 0.441; p=0.003
Abbreviations: TC—total cholesterol; TG—triglycerides; LDL-C—low-density lipoprotein cholesterol; CRP—C-reactive protein; 
ucMGP—undercarboxylated matrix Gla protein
Table 2. Spearman correlation analysis between circulating GRP, tested risk factors for CVD and biochemical parame-
ters in patients with or without coronary calcium deposits. Statistical significance was considered at p<0.05. 
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VC in the serum of CVD patients. It is not surprising 
that such positive relationship between circulating 
GRP and ucMGP as GRP is a component of a protein 
inhibitory complex (GRP–MGP–fetuin A) present at 
the sites of aortic valve calcification (7).
Our results demonstrate a clear trend for a de-
crease of total serum GRP with the increase of serum 
CRP for both CVD patients and in those with CACS 
>0. In addition, serum LDL levels also tend to in-
crease with the decrease of circulating GRP. It is well 
known that calcification and inflammation are inter-
connected processes contributing to atherosclerosis 
development. There are data showing that decreased 
GRP levels are linked with increased pro-inflamma-
tory responses of articular cells, and thus confirming 
the dual role of GRP—as calcification inhibitor and 
anti-inflammatory agent (19,20). Thus, it is consid-
ered that GRP may have strong implications in cal-
cification and/or inflammation-related diseases such 
as CVD (6). 
One of the limitations of the current study is 
the small number of studied patients. The GRP assay 
used for measuring circulating GRP cannot distin-
guish carboxylated and uncarboxylated GRP forms. 
Our study, for the first time, demonstrates a decrease 
in circulating total GRP in patients with CVD and 
in those with coronary calcium deposits. We have 
shown a significant relationship between circulating 
GRP and ucMGP confirming the notion that these 
two Gla proteins are components of a complex VC 
inhibitory system. An association between circulat-
ing GRP and serum CRP and LDL levels was dem-
onstrated, further contributing to the hypothesis re-
garding the dual role of GRP as a calcification inhib-
itor and an anti-inflammatory agent. Our findings 
add new information regarding the role of circulat-
ing GRP as a new player in calcification inhibition. 
CONCLUSION
Our study illuminates the link between total 
circulating GRP and CVD pathology and the degree 
of coronary calcification. However, further research 
is needed to fully elucidate the molecular mecha-
nisms of GRP action and to clarify its role as a poten-
tial novel valuable biomarker evaluating the develop-
ment and the degree of cardiovascular risk and VC. 
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